Carcinosarcoma is a rare malignant tumor with a biphasic morphology characterized by the presence of a malignant epithelial and mesenchymal component. It has been reported in many organs, including the genitourinary tract. We describe a case of a 47-year-old woman admitted to our hospital for history of recurrent urinary tract infection, dysuria and discharge of bloody fluid from the urethra at the end of urination. A tender palpable mass under the anterior vaginal wall was found and pathological examination showed a urethral carcinosarcoma. The histopathogenetic hypothesis and clinical management were considered in this report.

Keywords:
Carcinosarcoma, Urethral neoplasms, Epithelial and mesenchymal tumors
1.
Bermejo CE, Basler JW: Carcinoma of the urethra; in Hamdy FC, Basler JW, Catalona WJ (eds): Management of Urologic Malignancies. London, Churchill Livingstone, 2002, p 525.
2.
Frank I, Takahashi S, Tsukamoto T, Lieber M: Genitourinary sarcomas and carcinosarcomas in adults; in Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (eds): Genitourinary Oncology, ed 2. Philadelphia, Lippincott Williams & Wilkins, 2000, pp 1101-1119.
3.
Konno N, Mori M, Kurooka Y, Kameyama S, Homma Y, Moriyama N, Tajima A, Murayama T, Kawabe K: Carcinosarcoma in the region of female urethra. Int J Urol 1997;4:229-231.
4.
Jayamohan Y, Urs L, Rowland R, Woolums S, Lele SM: Periurethral carcinosarcoma. A report of 2 cases with a review of the literature. Arch Pathol Lab Med 2005;129:e91-e93.
5.
Liu J, Wu H: Carcinosarcoma of female urethra with melanocytic differentiation. Int J Clin Exp Pathol 2011;4:206-209.
6.
Komai Y, Urushibara M, Saito K, Sakai K, Morimoto S: A case of sarcomatoid carcinoma in the region of the female urethra. Nihon Hinyokika Gakkai Zasshi 2005;96:650-653.
7.
Thompson L, Chang B, Barsky SH: Monoclonal origin of malignant mixed tumors (carcinosarcoma): evidence for a divergent histogenesis. Am J Surg Pathol 1996;20:277-285.
8.
Oliva E, Amin MB, Jimenez R, Young RH: Clear cell carcinoma of the urinary bladder: a report and comparison of four tumors of mullerian origin and nine of probable urothelial origin with discussion of histogenesis and diagnostic problems. Am J Surg Pathol 2002;26:190-197.
9.
Lahoti C, Schinella R, Rangwala AF, Lee M, Mizrachi H: Carcinosarcoma of urinary bladder: report of 5 cases with immunohistologic study. Urology 1994;43:389-393.
10.
Di Marco DS, Di Marco CS, Zincke H, Webb MJ, Bass S E, Slezakc JM, Lightner DJ: Surgical treatment for local control of female urethral carcinoma. Urol Oncol 2004;22:404-409.
11.
Dalbagni G, Zhang Z-F, Lacombe L, Herr HW: Female urethral carcinoma: an analysis of treatment outcome and a plea for a standardized management strategy. Br J Urol 1998;82:835-841.
12.
Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G, Boehle A, Chevreau C, Paz-Ares L, Laufman LR, Winquist E, Raghavan D, Marreaud S, Collette S, Sylvester R, de Wit R: Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 2012;30:1107-1113.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.